Tracers / [68Ga]NOTA-MI-exendin-4

[68Ga]NOTA-MI-exendin-4

Also written as [Ga-68]Ga-NOTA-MI-exendin-4
Radionuclide
Ga-68 t½ 67.71 min
Modality
Therapy
Production route
—
Stage
Reported once
Syntheses indexed
2
Pancreatic beta-cell imagingDosimetry and biodistribution studiesPreclinical only, no clinical indication yet

What it is

Compound class
Exendin-4 peptide analogue conjugated to NOTA chelator via Met-Ile linker
Target / mechanism
GLP-1 receptor (GLP-1R) targeting PMID 37265006
Clinical application
—
Theranostic pair
—

Regulatory status

FDA
—
EMA (centralised)
—
Other approvals
—
Brand names
—

Clinical use

Typical injected activity
—
Uptake time
—

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesis—SPE—>98%NOTA-MI-exendin-4
piCHEM, Raaba-Grambach, Austria
37265006
2023 Mol Pharm
labeled with 68Ga by adding 2.5 M HEPES
——————40259061
2025 Eur J Nucl Med Mol Imaging

Need this precursor?We can point you to suppliers for [68Ga]NOTA-MI-exendin-4, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37265006. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37265006: 'Lys40[Mep((S-)NOTA-Met-Ile-Mal-)]exendin-4 (referred to as NOTA-MI-exendin-4)'.